Anavex Life Sciences Corp (AVXL)

[McMagyar]

I saw an expectation of hope in miraculous data be destroyed by short sellers who have other interests at heart other than treating Alzheimer's Diseased Patients successfully. The hoped for numbers regarding A2-73 are difficult to see in pooled data, as I just recently posted a story about 3 SubTypes of Alzheimer Disease sufferers. Not everyone who has ALzheimers is being effected by the disease in the same way, so it would make sense that by pooling data, that the data of those effectively treated with A2-73 would be washed out so to speak, by those who suffer a more aggressive AD. The adaptive trial for 32 Patients did NOT, I repeat Did NOT go to Maximum Therapeutic Dosage for all patients!
The 27 Paitients out of 32 continuing to take A2-73 signed up for an additional 2 Years-3 Years total. I wold hope as the Adapative Trial goes on that any of those patients not equalling the benefits of the A2-73 MonoTherapy Group will be allowed to adapt their medicines accordingly.

We know Insomnia was the number 1 noticed HAMD effect and that insomnia is a $32 Billion Market.
The good Dr. knows we just need to get Anavex in the supermarket, doesn't matter what isle you put it in..people will find it.